Skip to Content
Merck
CN
  • Characterization of cancer omics and drug perturbations in panels of lung cancer cells.

Characterization of cancer omics and drug perturbations in panels of lung cancer cells.

Scientific reports (2019-12-22)
Ayako Suzuki, Keiichi Onodera, Ken Matsui, Masahide Seki, Hiroyasu Esumi, Tomoyoshi Soga, Sumio Sugano, Takashi Kohno, Yutaka Suzuki, Katsuya Tsuchihara
ABSTRACT

To better understand the disruptions of transcriptional regulations and gene expression in lung cancers, we constructed a multi-omics catalogue of the responses of lung cancer cells to a series of chemical compounds. We generated and analyzed 3,240 RNA-seq and 3,393 ATAC-seq libraries obtained from 23 cell lines treated with 95 well-annotated compounds. To demonstrate the power of the created multi-omics resource, we attempted to identify drugs that could induce the designated changes alone or in combination. The basal multi-omics information was first integrated into co-expression modules. Among these modules, we identified a stress response module that may be a promising drug intervention target, as new combinations of compounds that could be used to regulate this module and the consequent phenotypic appearance of cancer cells have been identified. We believe that the multi-omics profiles generated in this study and the strategy used to stratify them will lead to more rational and efficient development of anticancer drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Minimum Essential Medium Eagle, HEPES Modification, with Earle′s salts, 25 mM HEPES and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell culture